Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Oregon Health and Science University
University of Massachusetts, Worcester
Information provided by (Responsible Party):
Applied Genetic Technologies Corp
ClinicalTrials.gov Identifier:
NCT00749957
First received: September 8, 2008
Last updated: March 6, 2013
Last verified: March 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2027
  Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)